KPE-00001175

KPE-00001175 is a pharmaceutical drug candidate developed by Kemin Pharma, a division of Kemin Industries. It belongs to a pipeline of small molecule compounds and purified botanical extracts investigated for their potential in treating inflammatory and infectious diseases. This pipeline was significantly expanded through the acquisition of Amalyte Pharmaceuticals in 2009, which brought in several preclinical and clinical-stage anti-inflammatory and anti-viral candidates. While Kemin Industries is widely recognized for its work in animal nutrition and human nutraceuticals, KPE-00001175 represents a traditional pharmaceutical effort. However, specific details regarding its molecular target, mechanism of action, and clinical progress are not publicly available, and the project is likely discontinued or inactive as the company has refocused on dietary supplement ingredients.